1. Lymphomas and reticuloendothelial neoplasms.
In: Ries LAG, Smith MA, Guney JG, et al, eds. Cancer Incidence
and Survival among Children and Adolescents: United States SEER
Program 1975-1995. Vol. Pub. No. 99-4649. Bethesda, MD:
National Cancer Institute SEER Program; 1999:35-50.
2. Cairo MS, Raetz E, Perkins SL. Non-Hodgkin’s lymphoma
in chidren. In: Kufe DW, Bast RC, Hait WN, et al, eds. Cancer
Medicine. 7th ed. Hamilton, ON: BC Decker; 2005:1962-1976.
3. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin’s
lymphoma in childhood. N Engl J Med. 1996;334(19):1238-1248.
4. Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer
incidence, survival, and mortality for children younger than age
15 years. Cancer. 1986;58(2 suppl):S598-S602.
5. Tumours of Haematopoietic and Lymphoid Tissues.
Washington DC: IARC Press; 2001.
6. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL. Childhood
and adolescent non-Hodgkin lymphoma: new insights in biology and
critical challenges for the future. Pediatr Blood Cancer. 2005;45(6):753-769.
7. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact
of age and gender on biology, clinical features, and treatment outcome
of non-Hodgkin lymphoma in childhood and adolescence. Br
J Haematol. 2005;131(1):39-49.
8. Murphy SB, Fairclough DL, Hutchison RE, Berard CW. Non-Hodgkin’s
lymphomas of childhood: an analysis of the histology, staging, and
response to treatment of 338 cases at a single institution. J
Clin Oncol. 1989;7(2):186-193.
9. Perkins SL. Work-up and diagnosis of pediatric non-Hodgkin’s
lymphomas. Pediatr Dev Pathol. 2000;3(4):374-390.
10. Murphy SB. Childhood non-Hodgkin’s lymphoma. N
Engl J Med. 1978;299(26):1446-1448.
11. Murphy SB. Classification, staging and end results of treatment
of childhood non-Hodgkin’s lymphomas: dissimilarities from
lymphomas in adults. Semin Oncol. 1980;7(3):332-339.
12. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic
strategies and classification. Br J Haematol. 2004;127(1):3-11.
13. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized
comparison between
rasburicase and allopurinol in children with
lymphoma or leukemia at high risk for tumor lysis.
Blood. 2001;97(10):2998-3003.
14. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized
international study of high-risk central nervous system B non-Hodgkin
lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736-2743.
15. Patte C, Auperin A, Gerrard M, et al. Results of the randomized
international FAB/LMB96 trial for intermediate risk B-cell
non-Hodgkin lymphoma in children and adolescents: it is possible
to reduce treatment for the early responding patients. Blood. 2007;109(7):2773-2780.
16. Atra A, Gerrard M, Hobson R, Imeson JD, Ashley S, Pinkerton
CR. Improved cure rate in children with B-cell acute lymphoblastic
leukaemia (B-ALL) and stage IV B-cell non-Hodgkin’s lymphoma
(B-NHL)–results of the UKCCSG 9003 protocol. Br
J Cancer. 1998;77(12):2281-2285.
17.Bowman WP, Shuster JJ, Cook B, et al. Improved
survival for children with B-cell acute lymphoblastic leukemia and
stage IV small noncleaved-cell lymphoma: a pediatric oncology group
study. J Clin Oncol. 1996;14(4):1252-1261.
18. Brecher ML, Schwenn MR, Coppes MJ, et al. Fractionated cylophosphamide
and back to back high dose methotrexate and cytosine arabinoside
improves outcome in patients with stage III high grade small non-cleaved
cell lymphomas (SNCCL): a randomized trial of the Pediatric Oncology
Group. Med Pediatr Oncol. 1997;29(6):526-533.
19. Cairo MS, Krailo MD, Morse M, et al. Long-term follow-up
of short intensive multiagent chemotherapy without high-dose methotrexate
(’Orange’) in children with advanced non-lymphoblastic
non-Hodgkin’s lymphoma: a children’s cancer group
report. Leukemia. 2002;16 (4):594-600.
20. Cairo MS, Sposto R, Hoover-Regan M, et al. Childhood and
adolescent large-cell lymphoma (LCL): a review of the Children’s
Cancer Group experience. Am J Hematol. 2003;72(1):53-63.
21. Cairo MS, Sposto R, Perkins SL, et al. Burkitt’s and
Burkitt-like lymphoma in children and adolescents: a review of the
Children’s Cancer Group experience. Br J Haematol. 2003;120(4):660-670.
22. Magrath I, Adde M, Shad A, et al. Adults and children with
small non-cleaved-cell lymphoma have a similar excellent outcome
when treated with the same chemotherapy regimen. J Clin
Oncol. 1996;14(3):925-934.
23. Patte C, Auperin A, Michon J, et al. The Societe Francaise
d’Oncologie Pediatrique LMB89 protocol: highly effective
multiagent chemotherapy tailored to the tumor burden and initial
response in 561 unselected children with B-cell lymphomas and L3
leukemia.
Blood. 1 2001; 97(11):3370-3379.
[PubMed: 11369626]
24. Patte C, Philip T, Rodary C, et al. Improved survival rate
in children with stage III and IV B cell non-Hodgkin’s
lymphoma and leukemia using multi-agent chemotherapy: results of
a study of 114 children from the French Pediatric Oncology Society. J
Clin Oncol. 1986;4(8):1219-1226.
25. Patte C, Philip T, Rodary C, et al. High survival rate in
advanced-stage B-cell lymphomas and leukemias without CNS involvement
with a short intensive polychemotherapy: results from the French
Pediatric Oncology Society of a randomized trial of 216 children. J
Clin Oncol. 1991;9(1):123-132.
26. Pillon M, Di Tullio MT, Garaventa A, et al. Long-term results
of the first Italian Association of Pediatric Hematology and Oncology
protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP
LNH92). Cancer. 2004;101(2):385-394.
27. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome
of B-cell acute lymphoblastic leukemia in childhood: a report of
three consecutive studies of the BFM group. Blood. 1992;80(10):
2471-2478.
28. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin’s
lymphomas of childhood and adolescence: results of a treatment stratified
for biologic subtypes and stage—a report of the Berlin-Frankfurt-Munster
Group. J Clin Oncol. 1995;13(2):359-372.
29. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment
results in childhood B-cell neoplasms with tailored intensification
of therapy: a report of the Berlin-Frankfurt-Munster Group Trial
NHL-BFM 90. Blood. 1999;94(10):3294-3306.
30. Spreafico F, Massimino M, Luksch R, et al. Intensive, very
short-term chemotherapy for advanced Burkitt’s lymphoma
in children. J Clin Oncol. 2002;20(12):2783-2788.
31. Woessmann W, Seidemann K, Mann G, et al. The impact of the
methotrexate administration schedule and dose in the treatment of
children and adolescents with B-cell neoplasms: a report of the
BFM Group Study NHL-BFM95. Blood. 2005;105(3):948-958.
32. Bradley MB, Cairo MS. Stem cell transplantation for pediatric
lymphoma: past, present, and future. Bone Marrow Transplant. 2008;41(2):149-158.
33. Del Toro G, Satwani P, Harrison L, et al. A pilot study
of reduced intensity conditioning and allogeneic stem cell transplantation
from unrelated cord blood and matched family donors in children
and adolescent recipients. Bone Marrow Transplant. 2004;33(6):613-622.
34. Miles RR, Cairo MS, Satwani P, et al. Immunophenotypic identification
of possible therapeutic targets in paediatric non-Hodgkin lymphomas:
a children’s oncology group report. Br J Haematol. 2007;138(4):506-512.
35. Perkins SL, Lones MA, Davenport V, Cairo MS. B-Cell non-Hodgkin’s
lymphoma in children and adolescents: surface antigen expression
and clinical implications for future targeted bioimmune therapy: a
children’s cancer group report. Clin Adv Hematol
Oncol. 2003;1(5):314-317.
36. Poirel HA, Heerema NA, Swansbury J, et al. In pediatric
mature B-cell non Hodgkin Lymphoma (NHL), complex karyotype or del(13q)
are linked prognostic factors in Burkitt lymphoma (BL) while 8q24/c-myc
rearrangement is associated with a strong adverse effect in diffuse
large B-cell Lymphoma (DLBCL). Blood. 2005 (abstract);106:1905.
37. Oschlies I, Klapper W, Zimmermann M, et al. Diffuse large
B-cell lymphoma in pediatric patients belongs predominantly to the
germinal-center type B-cell lymphomas: a clinicopathologic analysis
of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter
Trial. Blood. 2006;107(10):4047-4052.
38. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of
Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431-2442.
39. Rosenwald A, Wright G, Chan WC, et al. The use of molecular
profiling to predict survival after chemotherapy for diffuse large-B-cell
lymphoma. N Engl J Med. 2002;346(25):1937-1947.
40. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy
plus rituximab compared with CHOP alone in elderly patients with
diffuse large-B-cell lymphoma.
N Engl J Med. 2002;
346(4):235-242.
[PubMed: 11807147]
41. Cooney-Qualter E, Krailo M, Angiolillo A, et al. A phase
I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents
with relapsed/refractory CD20-positive non-Hodgkin’s
lymphoma: a Children’s Oncology Group study. Clin
Cancer Res. 2007;13(18 Pt 2):5652s-5660s.
42. Goldman S, Davenport G, Lynch JC, Perkins S, Shiramizu B,
Cairo MS. Rituximab (R) pharmacokinetics in pediatric patients with
newly diagnosed advanced stage mature B-cell lymphoma and leukemia: results
of a subpilot of COG Study ANHLO1P1. Pediatr Blood Cancer. 2006
(abstract);46(7):843.
43. Basso K, Margolin AA, Stolovitzky G, Klein U, Dalla-Favera
R, Califano A. Reverse engineering of regulatory networks in human
B cells. Nat Genet. 2005;37(4):382-390.
44. Lim M, Cairo MS. New therapeutic frontiers for childhood
non-Hodgkin’s lymphoma. In: Arceci R, Houghton P, eds. Molecularly-Targeted
Therapy for Childhood Cancer. New York, NY: Springer Publishing;
2010:177-214.
45. Stein H, Mason DY, Gerdes J, et al. The expression of the
Hodgkin’s disease associated antigen Ki-1 in reactive and
neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and
histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848-858.
46. Stein H, Foss HD, Durkop H, et al. CD30(+) anaplastic
large cell lymphoma: a review of its histopathologic, genetic, and
clinical features. Blood. 2000;96(12):3681-3695.
47. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic
large cell lymphomas. Semin Hematol. 2003;40(3):244-256.
48. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic
lymphoma kinase (ALK). Oncogene. 2001;20(40):5623-5637.
49. Falini B. Anaplastic large cell lymphoma: pathological,
molecular and clinical features. Br J Haematol. 2001;114(4):741-760.
50. Laver JH, Kraveka JM, Hutchison RE, et al. Advanced-stage
large-cell lymphoma in children and adolescents: results of a randomized
trial incorporating intermediate-dose methotrexate and high-dose cytarabine
in the maintenance phase of the APO regimen: a Pediatric Oncology
Group phase III trial. J Clin Oncol. 2005;23(3):541-547.
51. Mori T, Kiyokawa N, Shimada H, Miyauchi J, Fujimoto J. Anaplastic
large cell lymphoma in Japanese children: retrospective analysis
of 34 patients diagnosed at the National Research Institute for
Child Health and Development. Br J Haematol. 2003;121(1):94-96.
52. Rosolen A, Pillon M, Garaventa A, et al. Anaplastic large
cell lymphoma treated with a leukemia-like therapy: report of the
Italian Association of Pediatric Hematology and Oncology (AIEOP)
LNH-92 protocol. Cancer. 2005;104(10):2133-2140.
53. Brugieres L, Deley MC, Pacquement H, et al. CD30(+)
anaplastic large-cell lymphoma in children: analysis of 82 patients
enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92(10):3591-3598.
54. Reiter A, Schrappe M, Tiemann M, et al. Successful treatment
strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a
prospective analysis of 62 patients enrolled in three consecutive
Berlin-Frankfurt-Munster group studies. J Clin Oncol. 1994;12(5):899-908.
55. Sandlund JT, Pui CH, Santana VM, et al. Clinical features
and treatment outcome for children with CD30+ large-cell
non-Hodgkin’s lymphoma. J Clin Oncol. 1994;12(5):895-898.
56. Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin
lymphoma-type chemotherapy is efficacious treatment for pediatric
anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster
Group Trial NHL-BFM 90. Blood. 2001;97(12):3699-3706.
57. Williams DM, Hobson R, Imeson J, Gerrard M, McCarthy K,
Pinkerton CR. Anaplastic large cell lymphoma in childhood: analysis
of 72 patients treated on The United Kingdom Children’s
Cancer Study Group chemotherapy regimens. Br J Haematol. 2002;117(4):812-820.
58. Le Deley MC, Reiter A, Williams D, et al. Prognostic factors
in childhood anaplastic large cell lymphoma: results of a large
European intergroup study. Blood. 2008;111(3):1560-1566.
59. Damm-Welk C, Schieferstein J, Schwalm S, Reiter A, Woessmann
W. Flow cytometric detection of circulating tumour cells in nucleophosmin/anaplastic
lymphoma kinase-positive anaplastic large cell lymphoma: comparison
with quantitative polymerase chain reaction.
Br J Haematol. 2007;
138(4):459-466.
[PubMed: 17608768]
60. Damm-Welk C, Busch K, Burkhardt B, et al. Prognostic significance
of circulating tumor cells in bone marrow or peripheral blood as
detected by qualitative and quantitative PCR in pediatric NPM-ALK-positive
anaplastic large-cell lymphoma. Blood. 2007;110(2):670-677.
61. Brugieres L, Quartier P, Le Deley MC, et al. Relapses of
childhood anaplastic large-cell lymphoma: treatment results in a
series of 41 children–a report from the French Society
of Pediatric Oncology. Ann Oncol. 2000;11(1):53-58.
62. Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic
stem cell transplantation in relapsed or refractory anaplastic large
cell lymphoma of children and adolescents–a Berlin-Frankfurt-Munster
group report. Br J Haematol. 2006;133(2):176-182.
63. Sjostrom C, Seiler C, Crockett DK, et al. Global proteome
profiling of NPM/ALK-positive anaplastic large cell lymphoma. Exp
Hematol. 2007;35(8):1240-1248.
64. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II
study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s
lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764-2769.
65. Pulford K, Lamant L, Morris SW, et al. Detection of anaplastic
lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK
proteins in normal and neoplastic cells with the monoclonal antibody
ALK1. Blood. 1997;89(4):1394-1404.
66. Anderson JR, Jenkin RD, Wilson JF, et al. Long-term follow-up
of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin’s
lymphoma: a report of CCG-551 from the Childrens Cancer Group. J
Clin Oncol. 1993;11(6):1024-1032.
67. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type
therapy without local radiotherapy provides a 90% event-free
survival for children with T-cell lymphoblastic lymphoma: a BFM
group report. Blood. 2000;95(2):416-421.
68. Aghamohammadi A, Parvaneh N, Tirgari F, et al. Lymphoma
of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk
Lymphoma. 2006;47(2):343-346.
69. McClain KL, Joshi VV, Murphy SB. Cancers in children with
HIV infection. Hematol Oncol Clin North Am. 1996;10(5):1189-1201.
70. Jaffe ES. Primary body cavity-based AIDS-related lymphomas.
Evolution of a new disease entity. Am J Clin Pathol. 1996;105(2):141-143.
71. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization
classification of neoplastic diseases of the hematopoietic and lymphoid
tissues: report of the Clinical Advisory Committee meeting-Airlie House,
Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
72. Green M, Michaels MG, Webber SA, Rowe D, Reyes J. The management
of Epstein-Barr virus associated post-transplant lymphoproliferative disorders
in pediatric solid-organ transplant recipients. Pediatr
Transplant. 1999;3(4):271-281.
73. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy
for Epstein-Barr virus-positive post-transplantation lymphoproliferative
disease in children after solid organ transplantation. J
Clin Oncol. 20 2005;23(27):6481-6488.
74. Seidemann K, Tiemann M, Henze G, Sauerbrey A, Muller S,
Reiter A. Therapy for non-Hodgkin lymphoma in children with primary
immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr
Oncol. 1999;33(6):536-544.